NO982097D0 - Peptider - Google Patents

Peptider

Info

Publication number
NO982097D0
NO982097D0 NO982097A NO982097A NO982097D0 NO 982097 D0 NO982097 D0 NO 982097D0 NO 982097 A NO982097 A NO 982097A NO 982097 A NO982097 A NO 982097A NO 982097 D0 NO982097 D0 NO 982097D0
Authority
NO
Norway
Prior art keywords
peptides
Prior art date
Application number
NO982097A
Other languages
English (en)
Other versions
NO982097L (no
NO315238B1 (no
Inventor
Gustav Gaudernack
Ingvil Saeterdal
Jon Amund Eriksen
Mona Moeller
Marianne Klemp Gjertsen
Original Assignee
Norsk Hydro As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norsk Hydro As filed Critical Norsk Hydro As
Priority to NO19982097A priority Critical patent/NO315238B1/no
Publication of NO982097D0 publication Critical patent/NO982097D0/no
Priority to US09/674,973 priority patent/US6759046B1/en
Priority to PL99344341A priority patent/PL344341A1/xx
Priority to PCT/NO1999/000143 priority patent/WO1999058552A2/en
Priority to EP10183767.2A priority patent/EP2374814B1/en
Priority to JP2000548356A priority patent/JP4591983B2/ja
Priority to CNB998073555A priority patent/CN100355781C/zh
Priority to EP99940722.4A priority patent/EP1078000B1/en
Priority to ES10183767.2T priority patent/ES2463825T3/es
Priority to HU0101432A priority patent/HUP0101432A3/hu
Priority to CA2327549A priority patent/CA2327549C/en
Priority to AU54516/99A priority patent/AU755712B2/en
Priority to ARP990102199A priority patent/AR018346A1/es
Publication of NO982097L publication Critical patent/NO982097L/no
Priority to HK01107827A priority patent/HK1036997A1/xx
Publication of NO315238B1 publication Critical patent/NO315238B1/no
Priority to US10/776,224 priority patent/US7192927B2/en
Priority to US11/498,194 priority patent/US7863244B2/en
Priority to US12/983,510 priority patent/US8614177B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
NO19982097A 1998-05-08 1998-05-08 Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy NO315238B1 (no)

Priority Applications (17)

Application Number Priority Date Filing Date Title
NO19982097A NO315238B1 (no) 1998-05-08 1998-05-08 Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
AU54516/99A AU755712B2 (en) 1998-05-08 1999-05-03 Peptides
ES10183767.2T ES2463825T3 (es) 1998-05-08 1999-05-03 Péptidos que provocan inmunidad celular T
CA2327549A CA2327549C (en) 1998-05-08 1999-05-03 Peptides that induce t cell responses
PCT/NO1999/000143 WO1999058552A2 (en) 1998-05-08 1999-05-03 Peptides that ellicit t, cellular immunity
EP10183767.2A EP2374814B1 (en) 1998-05-08 1999-05-03 Peptides that ellicit T cellular immunity
JP2000548356A JP4591983B2 (ja) 1998-05-08 1999-05-03 ペプチド
CNB998073555A CN100355781C (zh) 1998-05-08 1999-05-03 肽
EP99940722.4A EP1078000B1 (en) 1998-05-08 1999-05-03 Peptides that ellicit t cellular immunity
US09/674,973 US6759046B1 (en) 1998-05-08 1999-05-03 Peptides
HU0101432A HUP0101432A3 (en) 1998-05-08 1999-05-03 Peptides that ellicit, cellular immunity
PL99344341A PL344341A1 (en) 1998-05-08 1999-05-03 Peptides
ARP990102199A AR018346A1 (es) 1998-05-08 1999-05-10 Peptidos mutantes promotores de la inmunidad celular t, composiciones farmaceuticas y vacunas formuladas con dichos peptidos para el tratamiento decanceres; uso de dichos peptidos, metodo para identificar dichos peptidos y secuencias de adn que codifican dichos peptidos mutantes y vectores y plasmid
HK01107827A HK1036997A1 (en) 1998-05-08 2001-11-08 Peptides
US10/776,224 US7192927B2 (en) 1998-05-08 2004-02-12 Peptides
US11/498,194 US7863244B2 (en) 1998-05-08 2006-08-03 Peptides
US12/983,510 US8614177B2 (en) 1998-05-08 2011-01-03 Peptides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO19982097A NO315238B1 (no) 1998-05-08 1998-05-08 Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy

Publications (3)

Publication Number Publication Date
NO982097D0 true NO982097D0 (no) 1998-05-08
NO982097L NO982097L (no) 1999-11-09
NO315238B1 NO315238B1 (no) 2003-08-04

Family

ID=19902021

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19982097A NO315238B1 (no) 1998-05-08 1998-05-08 Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy

Country Status (13)

Country Link
US (4) US6759046B1 (no)
EP (2) EP1078000B1 (no)
JP (1) JP4591983B2 (no)
CN (1) CN100355781C (no)
AR (1) AR018346A1 (no)
AU (1) AU755712B2 (no)
CA (1) CA2327549C (no)
ES (1) ES2463825T3 (no)
HK (1) HK1036997A1 (no)
HU (1) HUP0101432A3 (no)
NO (1) NO315238B1 (no)
PL (1) PL344341A1 (no)
WO (1) WO1999058552A2 (no)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO315238B1 (no) * 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
NO314086B1 (no) 1998-05-08 2003-01-27 Gemvax As Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
GB2361701A (en) * 2000-04-28 2001-10-31 Norsk Hydro As DNA polymerase delta mutants
GB0031430D0 (en) 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides
JPWO2003020306A1 (ja) * 2001-08-29 2004-12-16 伊東　恭悟 脱感作剤
AU2003232485A1 (en) 2002-04-18 2003-10-27 Mtm Laboratories Ag Neopeptides and methods useful for detection and treatment of cancer
EP1369126A1 (en) * 2002-04-18 2003-12-10 MTM Laboratories AG Use of coding microsatellite region frameshift mutation-derived peptides for treating cancer
US20050221350A1 (en) * 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
WO2004058157A2 (en) * 2002-12-16 2004-07-15 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
US7501486B2 (en) * 2004-09-07 2009-03-10 Burnham Institute For Medical Research Peptides that selectively home to heart vasculature and related conjugates and methods
CN101052408B (zh) * 2004-09-07 2013-03-27 伯纳姆研究院 选择性锚定到心脏脉管系统上的肽和相关结合物和方法
AU2005295317B2 (en) 2004-10-18 2011-10-13 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
BRPI0613025A2 (pt) * 2005-07-11 2010-12-14 Globeimmune Inc composiÇço para reduzir a resistÊncia a um agente, mÉtodo para a preparaÇço de um veÍculo de levedura e uso da composiÇço
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
WO2007101227A2 (en) * 2006-02-27 2007-09-07 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
PT2476435T (pt) 2006-08-11 2018-03-05 Life Sciences Res Partners Vzw Péptidos imunogénicos e a sua utilização em distúrbios imunitários
JP5579451B2 (ja) * 2007-03-19 2014-08-27 グローブイミューン，インコーポレイテッド ガンのための標的化治療の変異性回避の標的化アブレーションのための組成物
US20080293050A1 (en) * 2007-05-25 2008-11-27 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Gene analysis for determination of a treatment characteristic
EP2249855B1 (en) * 2008-02-14 2017-03-22 Life Sciences Research Partners VZW Immunogenic peptides and their use in transplantation
EP2247306B1 (en) 2008-02-14 2018-04-18 Life Sciences Research Partners VZW Immunogenic control of tumours and tumour cells
US20110111395A1 (en) 2008-02-14 2011-05-12 Jean-Marie Saint-Remy Cd4+cells with cytolytic properties
EP2244733B1 (en) 2008-02-14 2015-06-17 Life Sciences Research Partners VZW Immunotherapy targeting intracellular pathogens
EP2623125A1 (en) * 2008-02-14 2013-08-07 Life Sciences Research Partners VZW Elimination of immune responses to viral vectors
AU2009214040B2 (en) * 2008-02-14 2013-08-22 Katholieke Universiteit Leuven Strategies to prevent and/or treat immune responses to soluble allofactors
WO2010033841A1 (en) 2008-09-19 2010-03-25 Globeimmune, Inc. Immunotherapy for chronic hepatitis c virus infection
GB0821616D0 (en) 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
ES2661310T3 (es) 2009-03-09 2018-03-28 Bioatla, Llc Proteínas mirac
PL2643345T3 (pl) 2010-11-25 2021-08-16 Imnate Sarl Immunogenne peptydy do zastosowania w zapobieganiu i/lub leczeniu chorób zakaźnych, chorób autoimmunologicznych, odpowiedzi immunologicznych na czynniki allogeniczne, chorób alergicznych, nowotworów, odrzuceniu przeszczepów oraz odpowiedzi immunologicznych skierowanych przeciwko wektorom wirusowym stosowanym w terapii genowej lub szczepieniu genowym
RU2633503C2 (ru) * 2011-10-28 2017-10-12 Онкотерапи Сайенс, Инк. Пептиды торк и содержащие их вакцины
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
US20150045291A1 (en) * 2012-04-04 2015-02-12 Yeda Research And Development Co., Ltd. Lipopeptide conjugates comprising sphingolipid and hiv gp41 derived peptides
JP5890769B2 (ja) * 2012-12-13 2016-03-22 ループレヒト−カルルス・ウニヴェルジテート・ハイデルベルクＲｕｐｒｅｃｈｔ−Ｋａｒｌｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｈｅｉｄｅｌｂｅｒｇ がんの予防及び治療のためのｍｓｉ特異的なフレームシフトペプチド（ｆｓｐ）
US9205140B2 (en) 2012-12-13 2015-12-08 Ruprecht-Karls-Universität MSI-specific frameshift peptides (FSP) for prevention and treatment of cancer
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
US11207394B2 (en) 2014-11-26 2021-12-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mutated KRAS T cell receptors
IL293135A (en) 2015-05-13 2022-07-01 Agenus Inc A preparation containing at least two different complexes of purified stress protein linked to an antigenic peptide
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
JP2016028025A (ja) * 2015-07-29 2016-02-25 ループレヒト−カルルス・ウニヴェルジテート・ハイデルベルクＲｕｐｒｅｃｈｔ−Ｋａｒｌｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｈｅｉｄｅｌｂｅｒｇ がんの予防及び治療のためのｍｓｉ特異的なフレームシフトペプチド（ｆｓｐ）
CA2995771A1 (en) 2015-09-25 2017-03-30 Imcyse Sa Improved methods and compounds for eliminating immune responses to therapeutic agents
KR20180100302A (ko) * 2015-10-23 2018-09-10 우니베르지태트 트벤테 인테그린 결합 펩티드 및 그의 용도
KR102402444B1 (ko) * 2016-03-15 2022-05-27 엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름) 대상체가 췌관 선암을 앓을 위험을 평가하기 위한 초기 및 비 침습적 방법 및 이러한 질환의 치료 방법
BR112018071466A2 (pt) 2016-04-19 2019-03-19 Imcyse Sa novos peptídeos de ligação a cd1d imunogênicos
GB201608052D0 (en) * 2016-05-09 2016-06-22 Univ Oslo Hf T-cell receptors which recognise frameshift mutants of TGF-beta RII
WO2018039302A1 (en) * 2016-08-23 2018-03-01 The Cleveland Clinic Foundation Cancer treatment using cx26 blocking peptides
WO2018157773A1 (zh) * 2017-02-28 2018-09-07 暨南大学 一种促进创伤后组织修复与再生的修复肽及其应用
CN108503690B (zh) * 2017-02-28 2020-07-03 暨南大学 一种促进创伤后组织修复与再生的修复肽及其应用
WO2018223094A1 (en) 2017-06-02 2018-12-06 Arizona Board Of Regents On Behalf Of Arizona State University A method to create personalized canine cancer vaccines
US20200209241A1 (en) 2017-09-15 2020-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
AU2019261451A1 (en) 2018-04-26 2020-12-03 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
US20210213116A1 (en) 2018-07-26 2021-07-15 Frame Pharmaceuticals B.V. Cancer vaccines for kidney cancer
CA3106573A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for colorectal cancer
EP3827266A1 (en) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Cancer vaccines for uterine cancer
US20210162032A1 (en) 2018-07-26 2021-06-03 Frame Pharmaceuticals B.V. Cancer vaccines for breast cancer
CA3106574A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Arid1a, cdkn2a, kmt2b, kmt2d, tp53 and pten vaccines for cancer
FI3840767T3 (fi) 2019-05-29 2024-01-31 Hubro Therapeutics As Peptidejä
EP4038222A4 (en) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University METHODS AND COMPOSITIONS FOR IDENTIFYING NEOANTIGENS FOR USE IN THE TREATMENT AND PREVENTION OF CANCER
CN110734474B (zh) * 2019-11-29 2021-10-19 中山大学 一种抗菌肽的筛选方法及其应用
CN113061165A (zh) * 2020-01-02 2021-07-02 厦门大学 EB病毒BNLF2b基因编码多肽及其检测用途
EP4087389A4 (en) * 2020-01-09 2024-02-21 Univ Arizona State ANTIBODIES AND METHOD FOR PRODUCING ANTIBODIES
AU2021279327A1 (en) 2020-05-28 2022-12-22 Hubro Therapeutics As A peptide cocktail
WO2024052542A2 (en) 2022-09-09 2024-03-14 Hubro Therapeutics As A peptide cocktail

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9103974D0 (en) * 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
US5700638A (en) * 1993-08-26 1997-12-23 Washington University Cell death regulator
GB9410922D0 (en) * 1994-06-01 1994-07-20 Townsend Alain R M Vaccines
AU712441B2 (en) 1994-12-14 1999-11-04 Scripps Research Institute, The In vivo activation of tumor-specific cytotoxic T cells
US5866323A (en) * 1995-04-07 1999-02-02 Case Western Reserve University Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor β and homologous growth controlling factors
AU7142796A (en) 1995-10-02 1997-04-28 Erasmus University Rotterdam Diagnosis method and reagents
US5973018A (en) * 1995-10-04 1999-10-26 Owens-Corning Fiberglas Technology, Inc. Process for producing shaped phenolic foams
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
WO1998015285A1 (en) 1996-10-10 1998-04-16 The Wistar Institute Of Anatomy And Biology Methods and compositions for inducing a protective immune response to cancers
GB2328689A (en) * 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
NO315238B1 (no) * 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
NO314086B1 (no) 1998-05-08 2003-01-27 Gemvax As Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
GB0031430D0 (en) * 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides

Also Published As

Publication number Publication date
EP2374814B1 (en) 2014-03-19
EP2374814A3 (en) 2012-01-11
AR018346A1 (es) 2001-11-14
PL344341A1 (en) 2001-11-05
EP2374814A2 (en) 2011-10-12
WO1999058552A3 (en) 2000-03-02
US20070004632A1 (en) 2007-01-04
NO982097L (no) 1999-11-09
AU755712B2 (en) 2002-12-19
US8614177B2 (en) 2013-12-24
US7192927B2 (en) 2007-03-20
CN100355781C (zh) 2007-12-19
CN1305495A (zh) 2001-07-25
US20110105721A1 (en) 2011-05-05
HK1036997A1 (en) 2002-01-25
AU5451699A (en) 1999-11-29
CA2327549A1 (en) 1999-11-18
US6759046B1 (en) 2004-07-06
HUP0101432A3 (en) 2004-01-28
WO1999058552A2 (en) 1999-11-18
CA2327549C (en) 2014-10-07
US20050074849A1 (en) 2005-04-07
JP4591983B2 (ja) 2010-12-01
EP1078000B1 (en) 2017-03-29
US7863244B2 (en) 2011-01-04
NO315238B1 (no) 2003-08-04
JP2002519999A (ja) 2002-07-09
ES2463825T3 (es) 2014-05-29
EP1078000A2 (en) 2001-02-28
HUP0101432A2 (hu) 2001-08-28

Similar Documents

Publication Publication Date Title
NO982097D0 (no) Peptider
NO982098D0 (no) Peptider
ATE341990T1 (de) Sigmidoskop
DE69920011D1 (de) Rekombinanter venezolanische-equine-pferdeenzephalitis-virusimpstoff
DE59901560D1 (de) Retrograder tibianagel
DE59902874D1 (de) Buchsenkontakt
IS5585A (is) Lyfjaskömmtunarbúnaðir
NO20001494D0 (no) Overligger
DE59903966D1 (de) Exzenterzahnradgetriebe
ATE262513T1 (de) Benzoylpyridazine
DE59903106D1 (de) Tripode-gleichlaufdrehgelenk
DE59901046D1 (de) Methylcyclotetradec-5-en-1-one
FR2791348B1 (fr) POLYPEPTIDE Npt2B
DE59807217D1 (de) Nadellager
DE1118098T1 (de) Mehrfachflussigelektrosprühschnittstelle
ATE295417T1 (de) Angiostatin-bindendes protein
DE19842103B4 (de) Stanznietzuführung
DE59808995D1 (de) Endomikroskopsystem
DE59903616D1 (de) Rollenwicklerwalze
DE59902088D1 (de) Achrathermer Reimager
DE59900612D1 (de) Dispersionsazofarbstoffmischungen
NO20012283D0 (no) Koblede peptider
NO20013933D0 (no) Peptider
DE59901263D1 (de) Einzelplatz-sortierer
FR2770103B1 (fr) Bigoudi perfectionne

Legal Events

Date Code Title Description
MK1K Patent expired